Novartis Pharmaceuticals Corporation
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$124Mgeneral payments (2019-2025)
$9.6Mresearch payments (2019-2025)
224,097clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Kisqali $673K associated (2023-2025)
- Cosentyx $513K associated (2023-2025)
- Sandostatin $399K associated (2023-2025)
- Piqray $381K associated (2023-2025)
- Kesimpta $255K associated (2023-2025)
- Leqvio $252K associated (2023-2025)
- Scemblix $235K associated (2023-2025)
- Promacta $188K associated (2023-2025)
- Pluvicto $155K associated (2023-2025)
- Mayzent $106K associated (2023-2025)
- Ilaris $82K associated (2023-2025)
- Gilenya $70K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Szilard Voros | Stony Brook, NY | Cardiovascular Disease | $3,664,765.09 |
| John Cush | Dallas, TX | Rheumatology | $788,540.64 |
| Wendy Hein | Kansas City, KS | Pediatrics (Nurse Practitioner) | $425,684.85 |
| Leah Ehle | Manchester, CT | Adult Health (Nurse Practitioner) | $417,337.94 |
| Adissa Perez | Winter Park, FL | Nurse Practitioner | $366,504.55 |
| Kuldev Singh | Stanford, CA | Ophthalmology | $312,005.57 |
| Joseph Habboushe | New York, NY | Emergency Medicine | $308,707.00 |
| Graham Walker | Stanford, CA | Emergency Medicine | $308,707.00 |
| Karen Deshotel | Lafayette, LA | Nurse Practitioner | $260,690.29 |
| Kristen Pallok | Chicago, IL | Internal Medicine | $255,705.22 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.